Karoline Bechtold-Peters

Karoline Bechtold-Peters

Auto-generated profile, based on publicly available information

Karoline Bechtold-Peters

Novartis Pharma AG, TRD Biologics & CGT, GDD, 4002 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KWKlaus Wuchner
Klaus Wuchner
LYLinda Yi
Linda Yi
CCCyrille Chery
Cyrille Chery
FNFelix Nikels
Felix Nikels
FJFriederike Junge
Friederike Junge
VBVirginie Le Brun
Virginie Le Brun

21 August 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KWKlaus Wuchner
Klaus Wuchner
LYLinda Yi
Linda Yi
CCCyrille Chery
Cyrille Chery
FNFelix Nikels
Felix Nikels
FJFriederike Junge
Friederike Junge
VBVirginie Le Brun
Virginie Le Brun

21 September 2023 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KBKaroline Bechtold-Peters
Karoline Bechtold-Peters
ARAndrea Ruggiero
Andrea Ruggiero
NVNienke Vriezen
Nienke Vriezen
NINathan Ihle
Nathan Ihle
AKArmin Klein
Armin Klein
XWXiangyang Wang
Xiangyang Wang

21 October 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
AHAstrid Hauptmann
Astrid Hauptmann
GHGeorg Hoelzl
Georg Hoelzl
MMMartin Mueller
Martin Mueller
KBKaroline Bechtold-Peters
Karoline Bechtold-Peters
TLThomas Loerting
Thomas Loerting
In this work we use Raman spectroscopy for protein characterization in the frozen state. We investigate the behavior of frozen therapeutic monoclonal antibody IgG1 formulation upon thawing by Raman spectroscopy. Secondary and tertiary structure of the protein in three different mab formulations in the frozen state are followed through observation of marker bands for α-helix, β-sheet and random coil. We identify the tyrosine intensity ratio I856/I830 as a marker for mab aggregation. Upon fast cooling (40 °C/min) to -80 °C we observe a significant increase of random coil and α -helical structures, while this is not the case for slower cooling (20 °C/min) to -80 °C. Most changes in the protein's secondary structure are observed in the course of thawing in the range up to -20 °C, when passing through the glass transitions and cold-crystallization of the two types of freeze-concentrated solutions formed through macro- and microcryoconcentration. An increase of protein concentration and the addition of mannitol suppress secondary structural changes but do no impact on aggregation.

9 August 2017 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
EWEric Wakshull
Eric Wakshull
VQValerie Quarmby
Valerie Quarmby
HMHanns-Christian Mahler
Hanns-Christian Mahler
HRHongwen Rivers
Hongwen Rivers
DJDhananjay Jere
Dhananjay Jere
SGSwati Gupta
Swati Gupta

13 August 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
AGAnnick Gervais
Annick Gervais
EDEef H.C. Dirksen
Eef H.C. Dirksen
TPThomas Pohl
Thomas Pohl
KBKaroline Bechtold-Peters
Karoline Bechtold-Peters
WBWill Burkitt
Will Burkitt
LYLinda Yi
Linda Yi
Multi-attribute methods employing mass spectrometry are applied throughout the biopharmaceutical industry for product and process characterization purposes but are not yet widely accepted as a method for batch release and stability testing under the good manufacturing practice (GMP) regime, due to limited experience and level of comfort with the technical, compliance and regulatory aspects of its implementation at quality control (QC) laboratories. This article is the second part of a two-tiered publication aiming at providing guidance for implementation of the multi-attribute method by peptide mapping liquid chromatography mass spectrometry (MAM) in a QC laboratory. The first part [1] focuses on technical considerations, while this second part provides considerations related to GMP compliance and regulatory aspects. This publication has been prepared by a group of industry experts representing 14 globally acting major biotechnology companies under the umbrella of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Manufacturing & Quality Expert Group (MQEG).